BACKGROUND:Omalizumab treatment suppresses FcepsilonRI expression faster on blood basophils than skin mast cells. OBJECTIVE: We used omalizumab to elucidate the relative contributions of basophil versus mast cell FcepsilonRI activation in a nasal allergen challenge (NAC) model. METHODS:Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D(2) measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/FcepsilonRI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen-induced BHR was <20% of baseline or until day 45. Baseline visit procedures were repeated after the BHR reduction (midstudy NAC) and at the treatment period's completion (final NAC). RESULTS: Subjects treated with omalizumab who completed all NACs (n = 12) demonstrated significant mean reduction in BHR to an optimal dose of cat allergen by midstudy NAC compared with baseline (74% decrease; P = .001). In addition, these subjects demonstrated significant decreases in mean combined nasal symptom scores (50% decrease; P = .007) and total sneeze counts (59% decrease; P = .01) by midstudy NAC relative to baseline NAC. In contrast, measures of mast cell response (SPTT and nasal lavage prostaglandin D(2)) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAC symptom, or mast cell measures. CONCLUSION: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAC response. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND:Omalizumab treatment suppresses FcepsilonRI expression faster on blood basophils than skin mast cells. OBJECTIVE: We used omalizumab to elucidate the relative contributions of basophil versus mast cell FcepsilonRI activation in a nasal allergen challenge (NAC) model. METHODS: Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D(2) measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/FcepsilonRI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen-induced BHR was <20% of baseline or until day 45. Baseline visit procedures were repeated after the BHR reduction (midstudy NAC) and at the treatment period's completion (final NAC). RESULTS: Subjects treated with omalizumab who completed all NACs (n = 12) demonstrated significant mean reduction in BHR to an optimal dose of cat allergen by midstudy NAC compared with baseline (74% decrease; P = .001). In addition, these subjects demonstrated significant decreases in mean combined nasal symptom scores (50% decrease; P = .007) and total sneeze counts (59% decrease; P = .01) by midstudy NAC relative to baseline NAC. In contrast, measures of mast cell response (SPTT and nasal lavage prostaglandin D(2)) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAC symptom, or mast cell measures. CONCLUSION: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAC response. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: S S Saini; D W MacGlashan; S A Sterbinsky; A Togias; D C Adelman; L M Lichtenstein; B S Bochner Journal: J Immunol Date: 1999-05-01 Impact factor: 5.422
Authors: E C Hayes; D L Lombardo; Y Girard; A L Maycock; J Rokach; A S Rosenthal; R N Young; R W Egan; H J Zweerink Journal: J Immunol Date: 1983-07 Impact factor: 5.422
Authors: R M Naclerio; D Proud; A G Togias; N F Adkinson; D A Meyers; A Kagey-Sobotka; M Plaut; P S Norman; L M Lichtenstein Journal: N Engl J Med Date: 1985-07-11 Impact factor: 91.245
Authors: S S Saini; J J Richardson; C Wofsy; S Lavens-Phillips; B S Bochner; D W Macglashan Journal: J Allergy Clin Immunol Date: 2001-05 Impact factor: 10.793
Authors: Jonathan Corren; David Diaz-Sanchez; Andrew Saxon; Yamo Deniz; James Reimann; Don Sinclair; Teresa Davancaze; Daniel Adelman Journal: Ann Allergy Asthma Immunol Date: 2004-09 Impact factor: 6.347
Authors: Miya O Paterniti; Linda M Breslin; Jean-Paul Courneya; Patricia M Sterba; Robert G Hamilton; Donald W MacGlashan; Sarbjit S Saini Journal: J Invest Dermatol Date: 2013-12-23 Impact factor: 8.551
Authors: Jessica H Savage; Jean-Paul Courneya; Patricia M Sterba; Donald W Macglashan; Sarbjit S Saini; Robert A Wood Journal: J Allergy Clin Immunol Date: 2012-07-15 Impact factor: 10.793
Authors: A Thyagarajan; S M Jones; A Calatroni; L Pons; M Kulis; C S Woo; M Kamalakannan; B P Vickery; A M Scurlock; A Wesley Burks; W G Shreffler Journal: Clin Exp Allergy Date: 2012-08 Impact factor: 5.018
Authors: R S Gruchalla; H A Sampson; A H Liu; W Shreffler; P K Wallace; A Togias; G David; A Calatroni; P LeBeau Journal: Pediatr Allergy Immunol Date: 2016-02-18 Impact factor: 6.377